Should I buy or sell ViewRay stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ViewRay in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" VRAY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in VRAY, but not buy additional shares or sell existing shares. View VRAY analyst ratings or view top-rated stocks .

What is ViewRay's stock price target for 2024?

1 Wall Street analysts have issued twelve-month target prices for ViewRay's stock. Their VRAY share price targets range from $1.00 to $2.00. On average, they expect the company's stock price to reach $1.33 in the next year. View analysts price targets for VRAY or view top-rated stocks among Wall Street analysts .

How were ViewRay's earnings last quarter?

ViewRay, Inc. (NASDAQ:VRAY) announced its quarterly earnings results on Monday, February, 27th. The company reported ($0.15) earnings per share for the quarter, beating analysts' consensus estimates of ($0.16) by $0.01. The company earned $34.70 million during the quarter, compared to analysts' expectations of $34.65 million. ViewRay had a negative trailing twelve-month return on equity of 120.48% and a negative net margin of 104.30%. The business's quarterly revenue was up 70.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.16) EPS.

What is Scott Drake's approval rating as ViewRay's CEO?

5 employees have rated ViewRay Chief Executive Officer Scott Drake on Glassdoor.com . Scott Drake has an approval rating of 59% among the company's employees. This puts Scott Drake in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of ViewRay own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ViewRay investors own include Alibaba Group (BABA) , Amarin (AMRN) , Sorrento Therapeutics (SRNE) , TherapeuticsMD (TXMD) , Verastem (VSTM) , Corbus Pharmaceuticals (CRBP) , Viking Therapeutics (VKTX) , AbbVie (ABBV) , Accuray (ARAY) and Selecta Biosciences (SELB) .

When did ViewRay IPO?

ViewRay (VRAY) raised $52 million in an initial public offering (IPO) on the week of April 6th 2015. The company issued 4,000,000 shares at $12.00-$14.00 per share. Cowen and Company and Stifel acted as the underwriters for the IPO and BTIG and Brean Capital were co-managers.

Does ViewRay have any subsidiaries?

The following companies are subsidiares of ViewRay: Vesuvius Acquisition Corp., ViewRay GmbH, and ViewRay Technologies Inc.. Read More

NASDAQ:VRAY

ViewRay (VRAY) Stock Price, News & Analysis

→ Now Open: Crypto emergency update (From InvestorPlace) (Ad)

Free VRAY Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: N/A
50-Day Range: $0.03
▼
$0.65
52-Week Range: N/A

Volume: 108.50 million shs
Average Volume: 7.51 million shs
Market Capitalization: $4.59 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $1.33

Stock Analysis

Get ViewRay alerts:

ViewRay MarketRank™ Stock Analysis

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: ∞ Upside
$1.33 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: -1.57
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.51 out of 5 stars

3.0

Analyst's Opinion

Consensus Rating
ViewRay has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
ViewRay has received no research coverage in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for VRAY.

0.0

Dividend Strength

Dividend Yield
ViewRay does not currently pay a dividend.
Dividend Growth
ViewRay does not have a long track record of dividend growth.

4.4

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
ViewRay has received a 67.89% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "MRI machines", "Radiation therapy machines", and "Medical technology engineering" products. See details.
Environmental Sustainability
The Environmental Impact score for ViewRay is -1.57.

N/A

News and Social Media Coverage

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, ViewRay insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 2.50% of the stock of ViewRay is held by insiders.
Percentage Held by Institutions
92.97% of the stock of ViewRay is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of ViewRay is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of ViewRay is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad Crypto Swap Profits

Did You Get Your Free Bitcoin Yet?

And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.

>> Register right here

About ViewRay Stock (NASDAQ:VRAY)

ViewRay, Inc. designs, manufactures, and markets magnetic resonance imaging (MRI) guided radiation therapy systems to image and treat cancer patients in the United States, Italy, France, Taiwan, the United Kingdom, and internationally. It provides MRIdian, which is an MRI guided radiation therapy system that addresses beam distortion, skin toxicity, and other concerns. The company serves university research and teaching hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers through a network of direct sales force and distributors. ViewRay, Inc. was founded in 2004 and is headquartered in Denver, Colorado.

Ad Crypto Swap Profits

Did You Get Your Free Bitcoin Yet?

>> Register right here

VRAY Stock News Headlines

March 16, 2024 | finance.yahoo.com

VRAY Jan 2025 2.000 call

March 16, 2024 | finance.yahoo.com

VRAY Jan 2025 0.500 put

April 19, 2024 | American Alternative (Ad)

Your Money is Not Safe

Biden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…

March 16, 2024 | finance.yahoo.com

VRAY Jan 2025 0.500 call

March 16, 2024 | finance.yahoo.com

VRAY Jan 2025 3.000 put

November 4, 2023 | morningstar.com

ViewRay Inc VRAYQ

November 1, 2023 | benzinga.com

NUBURU Appoints Brian Knaley as new CEO

October 19, 2023 | tmcnet.com

Open Letter to ViewRay Customers, Service, Software Engineers and Suppliers-Let's Preserve ViewRay Technology

April 19, 2024 | American Alternative (Ad)

Your Money is Not Safe

October 17, 2023 | benzinga.com

Letter to ViewRay Lenders/Investment Bankers and Customers From Krishnan Suthanthiran, President/Founder of TeamBest Global Companies

August 20, 2023 | ca.finance.yahoo.com

ViewRay Inc (6L9.BE)

July 21, 2023 | seekingalpha.com

ViewRay stock to be delisted from Nasdaq and moved to OTC Exchange

July 21, 2023 | finance.yahoo.com

ViewRay® Announces Commencement of Nasdaq Delisting Proceedings: Common Stock Expected to Begin Trading on the OTC Markets

July 18, 2023 | benzinga.com

Why ViewRay Stock Hit A New 52-Week Low Today

July 18, 2023 | finanznachrichten.de

ViewRay, Inc.: ViewRay Files Voluntary Chapter 11 Petitions

July 17, 2023 | msn.com

Why ViewRay (VRAY) Stock Hit A New 52-Week Low Today

July 17, 2023 | investorplace.com

Why Is ViewRay (VRAY) Stock Down 69% Today?

July 17, 2023 | finance.yahoo.com

ViewRay® Files Voluntary Chapter 11 Petitions

July 7, 2023 | msn.com

ViewRay: Near-Term Bankruptcy Filing Might Be In The Cards - Sell

May 26, 2023 | fool.com

ViewRay (NASDAQ: VRAY)

May 25, 2023 | markets.businessinsider.com

Viewray (VRAY) Receives a Hold from Stifel Nicolaus

May 16, 2023 | finance.yahoo.com

Do You Believe in the Growth Prospects of ViewRay (VRAY)?

May 13, 2023 | msn.com

Morgan Stanley Maintains ViewRay (VRAY) Equal-Weight Recommendation

May 12, 2023 | finance.yahoo.com

Need To Know: The Consensus Just Cut Its ViewRay, Inc. (NASDAQ:VRAY) Estimates For 2023

May 12, 2023 | finance.yahoo.com

ViewRay's MRIdian® to be Featured at Leading European Radiation Oncology Meeting

May 11, 2023 | finanznachrichten.de

ViewRay, Inc.: ViewRay Announces First Quarter 2023 Results

May 11, 2023 | markets.businessinsider.com

B.Riley Financial downgrades Viewray (VRAY) to a Hold

See More Headlines

Receive VRAY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ViewRay and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/27/2023
Today: 4/18/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Electromedical equipment
Sub-Industry: N/A
Current Symbol: NASDAQ:VRAY
CUSIP: N/A
CIK: 1597313
Web: www.viewray.com
Phone: (440) 703-3210
Fax: 800-417-3459
Employees: 295
Year Founded: 2004

Price Target and Rating

Average Stock Price Target: $1.33
High Stock Price Target: $2.00
Low Stock Price Target: $1.00
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.60)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-107,330,000.00
Net Margins: -104.30%
Pretax Margin: -104.30%
Return on Equity: -120.48%
Return on Assets: -42.39%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.16
Quick Ratio: 0.91

Sales & Book Value

Annual Sales: $105.86 million
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.45 per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 183,402,000
Free Float: 178,817,000
Market Cap: $4.59 million
Optionable: Optionable
Beta: 0.81

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

Mr. Scott William Drake (Age 55)
Pres, CEO & Director
Comp: $1.8M
Mr. Robert S. McCormack J.D. (Age 56)
Chief Legal Officer
Comp: $692.36k
Dr. James F. Dempsey Ph.D. (Age 52)
Founder & Chief Scientific Officer
Mr. William P. Burke (Age 54)
Exec. VP & CFO
Drew Hill
Sr. VP of Operations & Devel.
Matt Harrison
Director of Investor Relations
Karen Hackstaff
VP of Marketing
Mr. Robert Michael Fuchs (Age 56)
Chief HR Officer
Dr. Martin Fuss M.D.
Ph.D., Chief Medical Officer
Mr. Paul Ziegler Jr. (Age 49)
J.D., Exec. VP & Chief Commercial Officer

Key Competitors

View All Competitors

Insiders

VRAY Stock Analysis - Frequently Asked Questions

Should I buy or sell ViewRay stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ViewRay in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" VRAY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in VRAY, but not buy additional shares or sell existing shares.
View VRAY analyst ratings or view top-rated stocks.
What is ViewRay's stock price target for 2024?: 1 Wall Street analysts have issued twelve-month target prices for ViewRay's stock. Their VRAY share price targets range from $1.00 to $2.00. On average, they expect the company's stock price to reach $1.33 in the next year.
View analysts price targets for VRAY or view top-rated stocks among Wall Street analysts.
How were ViewRay's earnings last quarter?: ViewRay, Inc. (NASDAQ:VRAY) announced its quarterly earnings results on Monday, February, 27th. The company reported ($0.15) earnings per share for the quarter, beating analysts' consensus estimates of ($0.16) by $0.01. The company earned $34.70 million during the quarter, compared to analysts' expectations of $34.65 million. ViewRay had a negative trailing twelve-month return on equity of 120.48% and a negative net margin of 104.30%. The business's quarterly revenue was up 70.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.16) EPS.
What is Scott Drake's approval rating as ViewRay's CEO?: 5 employees have rated ViewRay Chief Executive Officer Scott Drake on Glassdoor.com. Scott Drake has an approval rating of 59% among the company's employees. This puts Scott Drake in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of ViewRay own?: Based on aggregate information from My MarketBeat watchlists, some companies that other ViewRay investors own include Alibaba Group (BABA), Amarin (AMRN), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Verastem (VSTM), Corbus Pharmaceuticals (CRBP), Viking Therapeutics (VKTX), AbbVie (ABBV), Accuray (ARAY) and Selecta Biosciences (SELB).
When did ViewRay IPO?: ViewRay (VRAY) raised $52 million in an initial public offering (IPO) on the week of April 6th 2015. The company issued 4,000,000 shares at $12.00-$14.00 per share. Cowen and Company and Stifel acted as the underwriters for the IPO and BTIG and Brean Capital were co-managers.
Does ViewRay have any subsidiaries?: The following companies are subsidiares of ViewRay: Vesuvius Acquisition Corp., ViewRay GmbH, and ViewRay Technologies Inc..
Read More

This page (NASDAQ:VRAY) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

ViewRay (VRAY) Stock Price, News & Analysis

ViewRay MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

Company Ownership

Earnings and Valuation

About ViewRay Stock (NASDAQ:VRAY)

VRAY Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders

VRAY Stock Analysis - Frequently Asked Questions

Overall MarketRank^™